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GROUP TREATMENT EFFECTIVENESS FOR SUBSTANCE USE DISORDERS: 
ABSTINENCE VS. HARM REDUCTION 
Jill D. Parramore 
Old Dominion University, 2020 
Director: Dr. Nina G. Brown 
The purpose of this systematic review and meta-analysis was to compare group treatment 
effectiveness for substance use disorders within the U.S. across treatment philosophies as it 
relates to the primary research question, Is there a significant difference of group treatment 
effectiveness between Abstinence and Harm Reduction treatment philosophies? It was 
hypothesized that group treatment will remain an effective intervention to treat substance use 
disorders between treatment philosophies and that no significant differences exist between-group 
comparisons.  The aim of this study is to provide evidence of treatment effectiveness that will 
ultimately improve treatment outcomes for substance use disorders, provide guidance for broader 
implementation of evidence-based treatment approaches within the U.S., and to provide current 
information for evidence-based decision-making.   
Targeted studies included randomized and non-randomized controlled trials published in 
scholarly, peer-reviewed journals within the past 15 years, i.e. 2004-2020.  Targeted participants 
were individuals diagnosed with one or more substance use disorders and/or co-occurring 
disorders.  Treatment outcomes must be measured in quantitative methods with group treatment 
as the independent variable and substance use disorder outcomes as the dependent variables.  
The selected studies must indicate treatment philosophy used and provide a direct comparison of 
Abstinence and Harm Reduction.  Random-effects model meta-analysis was used to compute 
effect sizes for treatment outcomes to compare treatment philosophies.   
 Five studies met eligibility criteria (Miotto et al., 2012; Nyamathi et al., 2011; 
Rosenblum et al., 2005; Weiss et al., 2007; Weiss et al., 2009).  In four of the five included 
studies, the Harm Reduction condition outperformed the Abstinence condition.  However, the 
meta-analysis indicated that there was not a statistically significant difference between outcomes 
of substance use by treatment philosophy (Z = 1.29) and (P = 0.20).  However, there may be a 
clinically significant difference due to the aggregate standardized mean difference (-0.15, CI [-
0.38, 0.08]) which favors Harm Reduction over Abstinence in the reduction of substance use.  
Future research focused on clearly identified group treatment philosophy is imperative to provide 
up-to-date and a more accurate reflection on the effectiveness for treating substance use 
disorders.  
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The significant and devastating impact of substance use disorders on American lives and 
families has tasked counselors to ask a critical question, how effective is treatment within the 
U.S.?  By providing a comparison of group treatment effectiveness by treatment philosophy, this 
study aims to guide clinical practice to employ evidence-based interventions and to provide 
current information for evidence-based decision-making.  This systematic review follows 
protocols established in the Meta-Analysis Reporting Standards (MARS) (Cooper, 2018).  This 
chapter provides background, statement of the problem and research questions, purpose of the 
study, rationale, significance, delimitations, limitations, assumptions, and an overview of the 
study, key definitions, and remaining chapters. 
Background 
In 2018, an estimated 164.8 million, 60.2%, Americans ages 12 years old and older 
reported substance use within the past month and 20.3 million, 7.4%, had a specific substance 
use disorder according to the National Survey on Drug Use and Health (Substance Abuse and 
Mental Health Services Administration (SAMHSA, 2019).  The Diagnostic and Statistical 
Manual of Mental Disorders, (5th ed.; DSM-5; American Psychiatric Association, 2013) defines 
substance use disorder (SUD) as a pattern of behavior that creates significant distress and/or 
impairment in functioning due to use and misuse of  mood-altering substances such as caffeine, 
nicotine, alcohol, opioids, and other drugs.  To receive a diagnosis of a substance use disorder, 
an individual must meet at least two criteria related to substance use.  Examples of criteria 
include larger quantities of substance(s) use than intended, substance indulgence lasting longer 
than anticipated, inability to decrease or stop using a substance, and experiences of cravings and 
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urges to use substances.  The severity of the substance use disorder diagnosis is dependent upon 
the number of criteria present. Severity is indicated as a specifier such as mild, moderate, or 
severe.  The American Society of Addiction Medicine (ASAM) assessment is used to determine 
appropriate level of treatment for individuals with substance use disorders (SAMHSA, 2005).   
Treatment for Substance Use Disorders 
In 2018, 3.7 million, 1.4%, Americans aged 12 years old and older received treatment for 
substance use disorder(s) (SAMHSA, 2019).  Treatment for substance use disorders is 
conceptually viewed as different than treatment for other mental health disorders (DuPont et al., 
2015) where services and funding are provided by separate agencies and organizations than the 
rest of healthcare.  In the U.S., most services for SUDs are provided within treatment programs.  
Funding for SUD treatment is primarily provided by federal and state governments, such as 
block grants, and limited funding is provided by health care insurance (DuPont et al., 2015).  
Adequate funding is critical to treatment program effectiveness, to have the capacity to meet the 
community’s needs, and to ensure evidence-based treatment is implemented.  Currently, less 
than half of the treatment programs in the U.S. provide evidence-based treatment for substance 
use disorder (Padwa & Kaplan, 2017).  Some barriers to implementing evidence-based treatment 
are the segregation of SUD treatment from the rest of healthcare (DuPont et al., 2015), the time 
gap from dissemination research to clinical practice, and lasting effects of prior conceptions of 
the etiology of SUDs. 
In 2017, there were 13,585 treatment facilities in the U.S. where 82% offered outpatient 
(ASAM Level 1) treatment, 27% offered residential (ASAM Levels 2 and 3) treatment, and 5% 
offered hospital inpatient (ASAM Level 4) treatment (SAMHSA, 2018b).  More than half of the 
treatment facilities were operated by private non-profit organizations, 36% by private for-profit 
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organizations, and roughly 10% by local, state, federal, and tribal governments.  The operating 
structure of treatment facilities is an important consideration when evaluating program 
effectiveness.  Key stakeholders, legislature, and funding provide context to decisions in 
treatment program planning.  Key stakeholders differ depending on the structure of the 
organization, wherein consumers, i.e. individuals with SUDs, may or may not be considered as 
key stakeholders impacting who is able to contribute to programming decisions.  Recent efforts 
by the National Institute of Drug Abuse Clinical Trials Network (NIDA, 2015) have contributed 
to the adoption of evidence-based pharmacotherapies and behavioral therapies, such as 
cognitive-behavioral, contingency management, and motivation enhancement, within 
cooperating community-based treatment programs.   
Group Therapy   
Treatment programs for SUDs typically offer a standard set of short-term services such as 
individual, family, and group treatment (DuPont et al., 2015) and require attendance at outside 
self-help groups such as Alcoholics Anonymous or Narcotics Anonymous (SAMHSA, 2015a).  
Most programs offer group therapy as the primary modality of treatment, often with individual 
counseling sessions offered as an ancillary service or recommended as part of the aftercare plan 
(SAMHSA, 2015a).  Previous survey research indicates that more than 90% of treatment 
programs provide group therapy (Crits-Christoph et al., 2013; SAMHSA, 2010; SAMHSA, 
2018b; Weiss et al., 2004).  Group treatment is operationally defined as two or more unrelated 
individuals who meet to purposefully improve wellbeing.  Treatment programs generally offer 
group treatment by integrating cognitive-behavioral therapy, psychoeducation and skills 
development, interpersonal process groups, and specialized topics (SAMHSA, 2015a).  Group 
therapy as treatment as usual may be due to cost effectiveness; however, research indicates group 
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therapy is effective in treating substance use disorders in that the group experience offers 
curative forces that are not available in one-on-one counseling (Weiss et al., 2004).   
The decision to engage in treatment for a substance use disorder is also known as 
entering recovery.  The Substance Abuse and Mental Health Services Administration 
(SAMHSA, 2011) defines recovery as a process of change and provides guiding principles for 
counselors to promote these changes.  The principles of the recovery process are that it is person-
driven, holistic, culturally sensitive, and based upon respect.  As recovery is defined as a process 
of change, group therapy promotes personal growth, and is a catalyst for change.  Group therapy 
provides an opportunity to connect with others and to be understood.  The group leader utilizes 
group dynamics to promote interpersonal learning, healthy conflict resolution, emotional 
expression, empathy, and communication skills (Brown, 2009).   
To be an effective group leader for substance use disorders, counseling competencies and 
a specialized skill set in group process are required (SAMHSA, 2017) as the leader must 
simultaneously consider the needs of both the individual group members and of the group itself 
(Brown, 2009).  Group leaders provide a safe and trusting environment where individuals may 
self-disclose to other group members who have similar lived experiences (SAMHSA, 2015a).  
For example, those in the early stages of recovery may greatly benefit from those in the 
maintenance stage, and vice versa, as well as from the group leader.  By observing and learning 
from others the pitfalls and pinnacles of the recovery process, hope and encouragement is 
instilled in group members.  The group leader may structure expectations for change in that only 
the client has the power to change and can change, change does not pose a threat of danger to the 
client, and change is the only path toward obtaining one’s goals (Yalom, 2005).  Most treatment 
programs in the U.S. are focused on abstinence as the primary goal.  
5 
Treatment Philosophies 
Currently, there is no unified theoretical model comprehensively explains substance use 
disorders, nor is there a one-size-fits all treatment modality in working with those who 
experience substance use disorders (Skinner & Aubin, 2009; Straussner, 2012) and there is 
controversy in the field of counseling as two conflicting yet overlapping treatment philosophies, 
Abstinence and Harm Reduction, are guiding clinical practices for treating substance use 
disorders (Scott, 2015).  Therapeutic aims within the Abstinence treatment philosophy are for 
individuals to detoxify from all mood-altering chemicals and to maintain a drug and alcohol-free 
lifestyle without relapse.  In Harm Reduction, treatment outcomes are broadened from the ability 
to maintain abstinence to include any positive changes and reduction in harm.  The Harm 
Reduction treatment philosophy is aimed at maximizing the welfare of individuals with 
substance use disorders, whether they are committed to abstinence or not (Nutt, 2013).  A brief 
history of treatment philosophies is provided to explain the current dichotomy within the 
counseling profession. 
Historically, individuals with substance use disorders were perceived to lack morals.  The 
Moral Model of alcoholism was the first treatment philosophy of substance use disorders 
(Straussner, 2012).  Because of Prohibition, those with alcohol use disorder were stigmatized as 
‘sinners’ and ‘drunkards.’  It was thought that individuals were weak-willed, capable of making 
better decisions.  Many current laws reflect the Moral Model in that crimes committed while 
intoxicated are considered willful acts and should be punished.  Legislature, public policy, and 
criminal justice mandates influence standards of care.  These influences and fundamental 
segregation have resulted in punitive attitudes toward individuals with SUDs (Padwa & Kaplan, 
2017).  This model was replaced by the Disease Model, however, the stigma caused by the Moral 
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Model persists for people who struggle with substance use disorders and continues to influence 
treatment.   
The Disease Model is still used today and is the basis of the DSM-5 diagnosis of alcohol 
use disorder and other substance use disorders.  Substance use disorders are considered a disease 
as it is similar to other diseases in that it is preventable, treatable, and if left untreated, can last a 
lifetime.  The National Institute of Drug Abuse (2016) defines substance use disorder as “… a 
chronic, relapsing brain disease that is characterized by compulsive drug seeking and use, despite 
harmful consequences” (p. 5).  In 1952, Jellinek described alcoholism as a disease.  The disease 
progresses through stages of increased tolerance, loss of control, to chronic use (Jellinek, 1952).  
The rate of progression is dependent upon factors such as drug administration route, frequency, 
potency, and dosage.  Progression through the stages was thought to be irreversible until neural 
plasticity was discovered in the 1970’s (Sweatt, 2016).   
In the early stages of substance use, outcomes are pleasurable as neural networks, such as 
the dopaminergic and serotonergic pathways, are activated (Julien et al., 2011).  Hence, the 
stimulus of drug experimentation is reinforced by a positive response.  The positive response 
within the brain leads to associated learning and outcome expectancies develop.  Over time, 
neural networks adapt and the positive response to the drug will eventually decrease and the drug 
stimulus will become less effective.  Behavioral- and neuro-economics describe the process in 
which individuals begin to make decisions based on outcome expectancies that are no longer 
valid.  Because of learned associations of positive rewards received in early stages of substance 
use, individuals will choose short-term gains from mood-altering substances over long-term 
gains from abstinence due to the initial strength of response (Bickel et al., 2014; Hernnstein, 
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1997; Monterosso et al., 2012).  Substance use disorders are not the result of a single choice, 
they develop over countless choices.   
Substance use disorders are associated with cognitive impairments and deficits (Hagen et 
al., 2016).  Alcohol and opiates impair executive functioning, specifically in the ability to 
regulate emotions and to make decisions.  Cognitive dysfunction may lead to harmful behaviors 
(NIDA, 2016).  The inability to resist impulses to engage in harmful behaviors can be 
characterized as an impulse control disorder (Muresanu et al., 2012).  A common conception is 
that substance use disorder as an impulse control disorder where rewarding behaviors become 
habitual over time due to stimulus-response and action-outcome systems.   
Difficulties with impulse control contribute to problems associated with habit-forming 
behaviors.  Many would argue that substance use disorder is not a matter of choice, as without a 
normally functioning brain individuals are, at times, unable to make an informed decision to stop 
substance use (Julien et al., 2011).  Herrnstein (1997) would maintain that individuals are not 
able to make decisions that best maximize return in utility, as humans are meliorators and are 
unable to calculate all possible scenarios thus limiting their choice options to what has been 
experienced.  The choice to use a substance is efficient in some situations and not so in others.  
The long-term gains of not using substances is heavily discounted because the instant reward of 
alleviating negative reinforcers is highly efficient in most situations, especially during 
withdrawal (Bickel et al., 2014). 
Often individuals with substance use disorders will seek help because of negative 
consequences (Laudet, 2011).  However, even when faced with negative consequences, in the 
laboratory, most animals will continue to self-administer drugs (Wise & Koob, 2014).  The 
memory of the drug experience and its rewards are stored in the brain.  These stored memories 
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allow for such self-injurious temporal discounting to occur.  Temporal discounting is defined as 
the rate to which a reinforcer decreases in value as a function of delay (Bickel et al., 2013).   
Motivation toward drug-seeking increases because the memory of the drug experience elicits 
positive expectations of reward (Duka et al., 2011).  The value of immediate expected rewards 
reinforces the learned drug use behaviors.  Drug-seeking behavior is only extinguished when 
reinforcements, positive or negative, are no longer present (McNally, 2014).  This reasoning 
gave rise to Abstinence treatment, eliminating the possibility to experience further 
reinforcement.   
Abstinence  
Due to the lasting effects of stigma for having a substance use disorder, prior to 1970 
most treatment was received in self-help groups with peers and peer leaders, and not by 
professionals.  Currently, Abstinence treatment programs are offered on a continuum of levels of 
care for individuals with substance use disorders beginning with assessment and diagnosis, 
detoxification, inpatient and/or outpatient treatment, and aftercare including concurrent 
attendance at 12-Step self-help meetings such as Alcoholics Anonymous or Narcotics 
Anonymous.  Individuals who are unable to maintain abstinence during treatment often receive 
punitive consequences.  For example, if a relapse were to occur while receiving services, 
violation of program guidelines may lead to dismissal from the treatment program.  Relapse 
prevention is the primary therapeutic goal in this treatment philosophy. 
The Abstinence treatment philosophy, also commonly referred to as the Minnesota 
Model, is considered the traditional model for treating substance use disorders and is based on 
the Moral Model, the Disease Model, and 12-Step concepts.  Sussman (2010) summarizes 12-
Step concepts as a commitment to change in effort to maintain an abstinent lifestyle from all 
9 
mood-altering chemicals.  Theoretical underpinnings of Abstinence treatment suggest that the 
individual is powerless over their SUD, must surrender their ‘stinking’ thinking and adhere to 
group think mantra such as “Let go and let God,” and if one is unable to maintain abstinence that 
they have yet to ‘reach bottom’ and must endure more harm using in order to recover.  12-Step 
concepts are not grounded in empirical science, yet the ideology continues to be reflected in 
clinical practices and often inhibits the delivery of evidence-based treatment in many programs 
(Padwa & Kaplan, 2017).   
Many treatment providers believe in this treatment philosophy as it has been the status 
quo for many years.  Counselors assume that motivated individuals will immediately abstain and 
maintain abstinence from all mood-altering substance.  To assess a person’s willingness and 
readiness to change, counselors use the Transtheoretical Model to gauge motivation in relation to 
five stages of change: precontemplation, contemplation, preparation, action, and maintenance 
(Prochaska & DiClemente, 1984).  The stages are a framework to evaluate an individual’s 
current capability to acknowledge and to address substance use behaviors.  Group treatment 
provides an opportunity for interpersonal learning to progress through the stages of change.  
Those in the early stages of recovery may greatly benefit from those in later stages to 
breakthrough denial and those in the later stages accrue motivation to maintain abstinence from 
exposure to the ailments of those entering recovery (Stinchfield et al., 1994).  Motivation to 
maintain abstinence, measured over time, may be a predictor of future substance use (Korcha et 
al., 2011).  Treatment is often confrontational (Fisher & Harrison, 2013).   
Cook (1988) describes programs that use the Minnesota Model as “… intensive, offering 
group therapy, lectures, and counselling” (p. 625).  During the development of this treatment 
philosophy the DSM II categorized substance use disorder as a personality disorder and the 
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clinical zeitgeist of the times described individuals with SUDs as in need of psychodynamic 
changes to their inflated egos and defense mechanisms (White & Miller, 2007).  The clinical 
climate was influenced by Al-Anon, therapeutic communities such as Synanon, and prominent 
treatment providers and programs that used hostile and aggressive confrontation to break down 
defense mechanisms.  Although using a confrontational style has been shown to be ineffective 
and to cause harm (Kashner et al., 1992; Miller et al., 1993), it continues in group treatment 
practice today.  In a recent survey, 566 members of the Association for Addiction Professionals 
responded on a Likert-like scale where (1 = none/ almost none; 2 = some; 3 = half; 4 = most; 5 = 
almost all/ all) that between some and half (M = 2.35; SD = 1.20) of group sessions within a 
month’s time were spent using a confrontation style for the majority of the session (Wendt & 
Gone, 2017).   
Harm Reduction  
There is controversy and dichotomy within the field of counseling because the evolution 
of science and technology, such as findings from fMRI studies, has improved neurobiological 
understandings of substance use disorders since the development of Abstinence treatment 
philosophy.  New knowledge, reduced stigma, and paradigm shift in counselor attitudes toward 
individuals with SUDs have influenced a Harm Reduction treatment philosophy to emerge.  The 
Harm Reduction treatment philosophy is an acknowledgment that substance use disorders exist, 
are complex, and work must be done to minimize the harmful effects of drug use (Marlatt, 1996).  
Harm Reduction first emerged in the U.S. around 1990 as public health strategies for reducing 
risky behaviors related to substance use and HIV and the impact on people and communities 
(Heather et al., 1993).  Harm Reduction strategies include using a designated driver, syringe 
exchange programs, condom distribution, supervised safe injection sites, naloxone medication 
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distribution for opioid overdose, and medication-assisted treatment.  A comparison of 
Abstinence and Harm Reduction outcomes will be provided in Chapter 4, as there is no current 
literature comparing the two treatment philosophies. 
Harm Reduction, also commonly known as the Third Wave, is a social justice movement 
that promotes public health using humane, practical interventions that work toward minimizing 
the harmful effects of drug use for the individual and the community (Marlatt, 1996; Marlatt, 
1998; Vakharia & Little, 2016).  Treatment providers who adhere to this treatment philosophy 
“Recognize that the realities of poverty, class, racism, social isolation, past trauma, sex-based 
discrimination and other social inequalities affect both people’s vulnerability to and capacity for 
effectively dealing with drug-related harm” (Harm Reduction Coalition, 2018, p. 1).  Harm 
Reduction treatment providers are non-judgmental and non-coercive, convey a neutral stance 
toward substance use, and view the individual with substance use disorder as empowered with 
the volition of free will to create programs and policies to reduce the harm of their use (Vakharia 
& Little, 2016).  The individual with a substance use disorder is involved in treatment planning, 
program development and evaluation, and as a key stakeholder in decision making.  Treatment 
interventions are client-centered and trauma-informed, aimed at welcoming people as they are.  
Treatment providers develop a therapeutic alliance, collaborate on treatment goals that range 
from safer use to abstinence, and allow access to services to those who may not be abstinent.  
Treatment outcomes are often measured by quality of life for an individual and the community 
rather than solely based on days abstinent.    
Although the popularity of the Harm Reduction treatment philosophy is growing due to 
increasing evidence of its efficacy (Logan & Marlatt, 2014), Harm Reduction has not yet been 
adopted as a Federal policy for treating substance use disorders, with the exception of 
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medication-assisted treatment.  However, Harm Reduction treatments are usually accepted at 
State and local levels (Oyemade, 2015).  Research indicates medication-assisted treatment 
increases both the safety for the individual and for society (NIDA, 2012).  Medication-assisted 
treatment (MAT) includes therapeutic interventions and medication when treatment is medically 
necessary and appropriate (SAMHSA, 2014).  Neuro- and psychopharmacological approaches to 
treatment offer promising interventions for substance using individuals who are unwilling or 
unable to attain or maintain abstinence.  Medication-assisted treatment alters brain chemistry to 
reduce the impact of drug craving, and ultimately drug use (Haas-Koffler et al., 2014; Hone-
Blanchet et al., 2015; Peck & Ranaldi, 2014).   
Medication-assisted treatment is the most effective treatment for substance use disorders 
such as opioid use disorder (World Health Organization, 2009).  Medication-assisted treatment 
has been added to traditional services for treating substance use disorders.  MAT is used in 
treating tobacco, alcohol, and opioid use disorders.  The National Institute on Drug Abuse (2016) 
provide the following reasons to prescribe medication for substance abuse treatment: treating 
withdrawal, staying in treatment, and preventing relapse.  More than 90% of individuals with 
opioid use disorder (OUD) will relapse the first year following treatment (SAMHSA, 2014).  
Relapse is especially dangerous for individuals with opioid use disorder, as there is a high risk 
for overdose and fatal overdose.  When taken as prescribed, medication-assisted treatment allows 
for individuals to better function within society and to engage in counseling (Lingford-Hughes, 
2016).   
Statement of the Problem and Research Questions 
A review of group treatment effectiveness for treating substance use disorders within the 
U.S. is needed at this time.  The most recent systematic review and meta-analysis on 
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effectiveness of group treatment for adults with SUDs was conducted last year by Lo Coco et al. 
(2019).  Where Lo Coco and colleagues focused on overall effectiveness of group treatment by 
synthesizing global data from random controlled trials (RCTs), this review focuses on U.S. group 
treatment effectiveness by reviewing published outcomes of RCTs and other quality studies.  As 
an extension, group treatment effectiveness will be compared by treatment philosophy.  As the 
recent Opioid Epidemic has increased awareness of how critical treatment is, it is the role of 
counselors, who are ethically bound, to provide treatment interventions that are evidence-based 
(ACA, 2014).  The aim of this systematic review and meta-analysis is to provide an answer to 
the following primary research question: Is there a significant statistical and clinical difference in 
group treatment effectiveness when comparing group treatment by Harm Reduction or 
Abstinence treatment philosophies?     
RQ1: Is there a significant difference of group treatment effectiveness between 
Abstinence and Harm Reduction treatment philosophies?   
H1: It is hypothesized that group treatment will remain an effective intervention to treat 
substance use disorder between philosophies. 
Ho: There are no significant difference between group comparisons. 
Purpose of the Study 
The purpose of this study is to investigate whether group treatment is an effective 
treatment intervention for substance use disorders in the U.S. by comparing group treatment 
effectiveness for substance use disorders by treatment philosophies of Abstinence and Harm 
Reduction by reviewing and appraising the current literature.  The findings of this systematic 
review will help counselors to adhere to ethical guidelines of providing evidence-based 
interventions and to improve treatment outcomes for substance use disorders.  The findings of 
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this review will aid key stakeholders to make evidence-based decisions on treatment policies.  
Translating the findings of this study into practice will allow counselors to design and to 
implement treatment protocols that demonstrate effectiveness in the treatment of substance use 
disorder(s).  The aim of this systematic review is to provide further evidence for group treatment 
effectiveness by treatment philosophy.  The results of this study may ultimately provide further 
guidance for broader implementation of evidence-based treatment approaches in U.S. treatment 
programs and services for individuals with substance use disorders.  
Rationale 
This study will add to the current knowledge of the effectiveness of group treatment for 
substance use disorders and to extend the understanding of the impact of treatment philosophy on 
treatment outcomes, as no evidence of comparative effectiveness research on group treatment 
interventions by treatment philosophy was identified in the literature.  Group treatment is the 
dominant service provided in treating substance use disorders (SAMHSA, 2015a).  Examining 
the impact of group treatment on substance use will provide treatment providers with applicable 
knowledge to improve treatment programs and protocols.  Results of the comparative analysis 
may guide counselors to employ effective, evidence-based interventions.  This study will help to 
determine best practices and policies for treating substance use disorders. 
Significance 
 It has become urgent to elucidate effective treatment modalities for substance use 
disorders.  Considering the severe consequence of fatal overdose within the population that uses 
substances such as opioids, it is imperative that counselors provide evidence-based, effective 
treatment.  The field of counseling is in a current state of dichotomy where some providers 
require immediate abstinence and others may include medication-assisted treatment and strive 
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toward abstinence as a possible long-term goal.  This study will compare the competing 
treatment philosophies of Abstinence and Harm Reduction.  The contribution of this study is to 
provide up-to-date information on the effectiveness of treatment philosophies that will ultimately 
provide a basis to determine a more unified model of treating substance use disorder, as currently 
there is no unified theoretical model that comprehensively explains all aspects of substance use 
(Skinner & Aubin, 2010).   
Delimitations 
 Systematic reviews typically include only the most rigorous studies on a given topic, such 
as randomized controlled trials and controlled clinical trials.  The target of this study is applied 
research, where treatment for substance use disorder is provided by community-based programs 
and not in laboratories.  Random design and/or control groups for comparison are often not 
imposed in applied research where consumers of the treatment programs require immediate help 
and are ethically bound to receive services.  Due to this departure from standard practice of 
excluding less than rigorous studies, bias will be a risk factor to the conclusions of this study.  
Risk bias assessment tools will be used to reduce the bias.  
 Direct comparisons of treatment approach and group treatment interventions will be 
difficult to obtain, as currently there are no standardized measurements of treatment effect for 
substance use disorder limiting the ability to investigate treatment efficacies across studies 
(Tiffany et al., 2011).  This study will include outcome measures presented in the included 
studies, but those measures may have to be expanded or collapsed to meet requirements for 
statistical power (Balkin & Sheperis, 2011).  Heterogeneity of effect sizes and quality of 
individual studies will be investigated prior to conducting meta-analyses and statistical 
adjustments will be implemented, as needed.    
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  Limitations 
There is a possibility that a low number of studies will meet the criteria of this study 
impacting the generalizability of the results.  Group treatment effectiveness may not be 
investigated often due to the difficulty of rigorous design in the delivery of services and 
measuring treatment outcomes.  This is partially due to practical limitations of clinical settings 
and ethical concerns when considering control or comparison groups.  Attrition and open 
enrollment groups wherein attendance varies from session to session and structured delivery of 
treatment which builds over time is not possible further compound the ability to establish strong 
research support (Wendt & Gone, 2017).  Many moderating, mediating, and confounding 
variables exist in this type of applied research.  Some examples are treatment fidelity, such as 
therapist adherence to treatment philosophy and counselor competence as a group leader (Collyer 
et al., 2019), therapeutic alliance, and group cohesion (Orchowski & Johnson, 2012).   
Assumptions 
 This study is based on the conceptual framework of prior theory and research, utilizing 
the paradigm of post-positivism, in that the purpose of this study is to arrive at a conclusion of 
effectiveness by comparison that will guide clinical practice and policies for SUD treatment.  
The primary assumption is that this study will employ rigorous measures to minimize erroneous 
conclusions, as the quality of the systematic review is dependent on its methodology.  The 
secondary assumption is that systematic reviews provide better evidence than individual studies 
in comparative effectiveness research (Berlin & Cepeda, 2012).  By identifying and critically 
appraising all existing literature based on eligibility criteria, the researcher can synthesize the 
findings of multiple studies to answer a specific research question.  The third, and ultimately, the 
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purpose of this study, is that systematic reviews inform clinical practice and policies (Henly, 
2016; Higgins & Green, 2008). 
Overview of Study and Key Definitions 
This review will be conducted systematically.  The full protocol for this systematic 
review was not previously published; however, it is detailed within this manuscript.  Scholarly, 
peer-reviewed journal articles focused on group treatment interventions used in treating 
substance use disorders will be targeted in a search strategy of online databases.  Randomized 
and non-randomized controlled trials studying the effects of group treatment interventions in 
Abstinence and Harm Reduction treatment philosophies of substance use disorders are the 
targeted type of studies for this review; however, less rigorous designs will be assessed for 
inclusion due to the nature of this type of intervention.  Restrictions will be made on publication 
status, publication dates, or published language of each study.  Targeted studies will be published 
in scholarly, peer-reviewed journals within the past 15 years, i.e. 2004-2019, performed in the 
U.S., and written in the English language.   
Titles and abstracts will be reviewed to determine initial inclusion to the systematic 
review.  The manuscripts of the initial studies will be further reviewed to decide whether 
inclusion criteria are sufficiently met.  Those selected for inclusion will be assessed for quality, 
methodological heterogeneity, and risk of bias.  The GRADE approach will assess for quality 
and a level of strength will be provided for each study (Higgins & Green, 2008).  Methodological 
heterogeneity will be assessed, and a statistical value will be assigned as I2.   Risk of bias of 
included studies will be assessed using the Cochrane Collaboration tool 2 (Higgins et al., 2011).  
Methods of data collection and data synthesis will be described in Chapter III and results will be 
provided in Chapter IV.  Results of individual studies and synthesis of results as an aggregate 
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standardized mean difference will be provided as a comparison of group treatment effectiveness 
for substance use disorders by treatment.  Definitions of key terms are provided.   
Definition of Key Terms 
Abstinence – Treatment philosophy which focuses on abstinence as the primary goal for 
individuals with substance use disorders. 
Comparative effectiveness research (CER) – A systematic review of two or more treatment 
modalities that directly compares the harms and benefits to improve the quality of services. 
Co-occurring disorder – Concurrent diagnoses of one or more substance use disorders and one or 
more mental health disorder. 
Group treatment – Two or more unrelated individuals who meet to purposefully improve 
wellbeing. 
Harm Reduction – Treatment philosophy which focuses on reducing harm of substance use 
disorders and may include abstinence as a goal, other goals include any progress toward positive 
changes. 
Meta-analysis – Statistical procedure which measures effect size across multiple studies. 
Medication-assisted treatment – Pharmacological interventions for substance use disorders. 
Random-effects model meta-analyses assumes heterogeneity within and between studies. 
Substance use disorder – Consumption of mood-altering substances that interferes with daily 
functioning, must meet at least two criteria as defined in the DSM 5. 
Systematic review – A literature review that follows specific protocols to appraise individual 
studies and synthesize outcomes. 
Treatment for Substance Use Disorders – Therapeutic services offered by a trained professional, 
usually delivered in treatment programs. 
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Overview of Remaining Chapters 
 Chapter I presented an introduction to the proposed research comparing the effectiveness 
of group treatment for substance use disorders by treatment philosophies Abstinence and Harm 
Reduction.  Background for the study was provided including treatment for substance use 
disorders, group therapy, and Abstinence and Harm Reduction treatment philosophies.  The 
statement of the problem and research questions were described.  The purpose, rationale, and 
significance of the study were presented.  The delimitations, limitations, and assumptions of the 
study are summarized.   A definition of key terms and an overview of remaining chapters was 
provided.   
Chapter II presented a literature review that establishes the need for an up-to-date review 
of group treatment effectiveness for substance use disorders within the U.S.  Literature reviewed 
included previous systematic reviews with meta-analyses, narrative, or qualitative summaries.  
To date, no systematic review and meta-analysis was found comparing the effectiveness of group 
treatment by treatment philosophies Abstinence and Harm Reduction.  A summary was provided.   
In Chapter III, the methodological design of the proposed study was described.  Study 
selection protocol such as inclusion and exclusion criteria, search strategy, and information 
sources was provided.  Data collection, methods for assessing risk to internal validity, and 
summary measures were defined.  Data collected from selected studies included study 
characteristics such as patient population demographics, design, objective, setting, and primary 
outcome(s).  Intervention effects and comparison information were also collected.  Four main 
threats to internal validity were discussed.  Summary measures included methods of synthesis, 
publication bias, and selective reporting. 
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Chapter IV includes study selection, study characteristics, results of individual studies, 
synthesis of results, and a summary of findings.  Measures of quality, heterogeneity, and risk of 
bias were provided.  Assessment of internal validity of individual studies including publication 
and reporting biases were described.  Adverse and harmful effects concluded the results section 
of this study. 
Chapter V provided a review of the previous chapters, summary of the evidence, 
generalizability, conclusions, and implications.  The aim of this systematic review and meta-
analysis was to provide an answer to the following primary research question: Is there a 
significant statistical and clinical difference in group treatment effectiveness when comparing 
group treatment by Harm Reduction or Abstinence treatment philosophies?  Main findings of the 
synthesis, alternative explanations for observed results, and similarities and differences from 
previous syntheses were provided.  Generalizability of conclusions including implications for 
related populations, intervention variations, and treatment outcomes was discussed.  Implications 












BACKGROUND OF THE STUDY 
The primary purpose of this literature review is to establish the need for a review of 
group treatment effectiveness for substance use disorders (SUDs) by treatment philosophy within 
the U.S.  Although group treatment is deemed treatment as usual for most programs, existent 
literature focused on group treatment for substance use disorders is scarce (Wendt & Gone, 
2017).  Considering the wide acceptance of group treatment as an effective and evidence-based 
intervention, the gap in the literature is concerning.  To date, no systematic review and meta-
analysis was found comparing the effectiveness of group treatment by treatment philosophies 
Abstinence and Harm Reduction.  Comparing the effectiveness of treatment philosophies will 
add to current knowledge of treatment for SUDs.  Literature reviewed, appraised, and 
synthesized includes previous systematic reviews with meta-analyses, narrative, or qualitative 
summaries. 
Previous Syntheses 
Prendergast et al. (2002) investigated the effectiveness of substance use treatment and 
conducted a meta-analysis on 78 studies published from 1965 to 1996.  While there was no 
special attention given to group treatment in the review, significant effects were found.  
Outcomes for individuals who received treatment for SUDs had an adjusted average effect size 
of 0.34 for substance use and 0.16 for crime-related measures.  Effect sizes of 0.20 are 
considered small, 0.50 medium, or 0.80 and greater as large (Cohen, 1988).  Prendergast and 
colleagues concluded: 
Considering the positive results from this meta-analysis, as well as the findings from 
other meta-analyses and narrative reviews of drug treatment, it would seem appropriate to 
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cease asking whether treatment for drug abuse is effective and begin asking instead how 
treatment can be improved and how it can be tailored to the needs of different types of 
clients (p. 66). 
Toward that purpose, six previous syntheses were identified in the literature that provide 
further evidence regarding group treatment effectiveness for substance use disorders (Engle & 
MacGowan, 2009; Lo Coco et al., 2019; Orchowski & Johnson, 2012; Sobell & Sobell, 2011; 
Sokol et al., 2018, Weiss et al., 2004).  There were several reviews of related interest but were 
not included due to lack of reporting, results, or focus on group treatment as the independent 
variable and/or treatment outcomes for substance use disorder (Amato et al., 2011; Burlingame 
et al., 2013; Cleary et al., 2008; Drake et al., 2008; Dugosh et al., 2016; Hess, 2009; Hunt et al., 
2014; Jiang et al., 2017; Klimas et al., 2014; Magill & Ray, 2009; Pennay et al., 2011; Roberts et 
al., 2015; Tanner-Smith et al., 2011; Waldron & Turner, 2008). 
In a narrative review, Weiss and colleagues (2004) found only 24 studies comparing 
outcomes of group treatment for SUDs.  The studies were categorized into six research designs 
by the primary treatment employed which included four studies on group therapy vs. no group 
therapy (Luthar & Suchman, 2000; Razavi, 1999; Stephens et al., 2000; Weiss et al., 2000), three 
studies on group therapy vs. individual therapy (Graham et al., 1996; Marques & Formigoni, 
2001; Schmitz et al., 1997), one study on group therapy plus individual therapy vs. individual 
therapy alone (Linehan et al., 1999), two studies on group therapy plus individual therapy vs. 
group therapy alone (Crits-Christoph et al., 1999; McKay et al., 1997), 13 studies on group 
therapy vs. specialized group therapy (Annis, 1979; Eriksen et al., 1986; Ito et al., 1988; 
Joanning et al., 1992; Kadden et al., 1989; Kadden et al., 2001; Kaminer et al., 2002; Martin et 
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al., 1996; Olson et al., 1981; Omer et al., 1998; Pomerleau et al., 1978; Smith et al., 2001; Telch 
et al., 1984), and one study on more group therapy vs. less group therapy (Coviello et al., 2001).   
In comparisons for group therapy vs. no group therapy, results from studies three of the 
four studies indicated effectiveness of group therapy when added to treatment as usual (TAU) or 
when compared to a controlled condition.  Luthar and Suchman (2000) compared group 
treatment vs. TAU of methadone maintenance for 261 participants with heroin use disorder and 
found significant improvements in reduced opioid use and improved child maltreatment, parent-
child interaction, and overall adjustment when randomly assigned to a specialized relational 
group therapy in addition to treatment as usual, methadone maintenance counseling.  Stephens et 
al. (2000) randomly assigned 291 adults to three conditions, including 14-week cognitive 
behavioral treatment in a closed group designed for relapse prevention, three individual 
treatment sessions consisting of initial assessment and two brief follow-ups, and a delayed 
condition that received no treatment for four months.  Results indicated that all conditions 
significantly improved over time, but the two treatment conditions demonstrated better results at 
the four-month measure (d = 1.01 and .85).  Weiss et al. (2000) randomly assigned 45 
individuals with co-occurring disorders of bipolar and substance use disorder to attend 12 to 20 
weeks of integrated group treatment or to attend only monthly assessments without group 
treatment, with attempts to hold other treatment factors stable such as treatment as usual.  Those 
who participated in group treatment had significantly better outcomes than those in the control 
condition with both scores on the Addiction Severity Index and in length of abstinence.  The 
fourth study by Razavi et al. (1991) demonstrated no significant differences for outcomes when 
comparing treatment conditions of self-help group, professionally-led group, and no group for 
993 participants for tobacco use disorder.  
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For comparisons of group therapy vs. individual therapy, substance use improved 
significantly overall; however, the reviewers were unable to distinguish differences between 
group and individual treatment outcomes and suggested that the two psychosocial interventions 
are equivalent.  Graham et al. (1996) assigned 192 patients with a substance use disorder to 12 
weeks of relapse prevention treatment, either group or individual therapy.  There were no 
significant differences between conditions for treatment outcomes, measured by formal 
assessments for alcohol use (d = .14).  Marques and Formigoni (2001) assigned 155 patients with 
a substance use disorder to group or individual cognitive-behavioral therapy for 17 sessions upon 
completing inpatient treatment.  There were no significant differences between conditions for 
treatment outcomes, measured by formal assessment for substance use (d = .25).  Similarly, there 
were no significant differences found between group and individual treatment modalities for the 
majority of outcome measures in a study conducted by Schmitz et al. (1997) where 32 patients 
with cocaine use disorder were assigned to 12 sessions of either individual or group treatment.  
However, patients in the group condition reported less days using cocaine during treatment than 
did the individual condition.   
To extend the study conducted by Weiss et al. (2004), Sobell and Sobell (2011) included 
a fourth study by Duckert et al. (1992) that focused on comparing group and individual treatment 
for substance use disorder where 135 males with alcohol use disorder were randomly assigned to 
12 sessions of either individual or group cognitive-behavioral therapy. Similarly, no significant 
differences were found between conditions for treatment outcomes, including alcohol use.  
Sobell and Sobell concluded that the gap in the literature of research on the efficacy of group 
therapy may be due to the difficulty of delivering the same type of treatment in a group versus an 
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individual session thus limiting comparative effectiveness research, and because of differential 
attrition whereby individuals are more likely to drop out when assigned to group therapy.   
When Weiss and colleagues (2004) compared group therapy plus individual therapy vs. 
group therapy alone or individual therapy alone, results were mixed.  Crits-Christoph et al. 
(1999) randomly assigned 487 participants with cocaine use disorder to one of four treatment 
conditions, group alone, group plus cognitive behavioral therapy, group plus supportive-
expressive therapy, and group plus individual therapy.  There were no significant differences 
amongst treatment comparisons except for group plus individual therapy which results in better 
treatment outcomes as indicated by scores on the Addiction Severity Index.  In contrast, Linehan 
et al. (1999) randomly assigned 28 participants with one or more SUDs and borderline 
personality disorder to one-year of either TAU which consisted of individual therapy and case 
management or to dialectical behavioral therapy (DBT) plus group.  Results indicated outcomes 
for substance use were significantly better for the DBT plus group treatment condition at both 
the four-month and 16-month assessments (d = 1.03).  McKay et al. (1997) randomly assigned 
98 participants to either group alone or group plus individual relapse prevention therapy.  Results 
indicated each treatment condition was superior when compared at different times.  At the 3-
month follow-up, participants assigned to group plus individual had better results for substance 
use measured by self-report and urinalysis (d = .59); however, participants assigned to group 
alone demonstrated better results at the 6-month follow-up. 
When Weiss and colleagues (2004) compared group treatments by content and theoretical 
orientation, there was one comparison that relates to the inquiry of this study.  Pomerleau and 
colleagues (1978) compared behavioral group therapy with the treatment goal of reduced alcohol 
use to “traditional” treatment with abstinence as the treatment goal.  Group treatment included 
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12-weeks of 90-minute sessions followed by five maintenance sessions over a nine-month 
period.  Of the 32 randomly assigned individuals with substance use disorders, 24 were present 
for the one-year follow up where self-report and liver functioning was measured.  Individuals in 
the behavioral group therapy demonstrated greater reduction in alcohol use and greater retention 
in treatment than did individuals in the “traditional” treatment group. 
Engle & MacGowan (2009) conducted a narrative review on the efficacy of group 
treatment for adolescents.  Of the 12 studies, only two met criteria of Chambless and Hollon’s 
(1998) criteria of efficaciousness (Waldron et al., 2000; Liddle et al., 2001).  It was reported in 
these two studies that the experimental conditions outperformed control conditions at the 7- and 
12-month follow-up on treatment outcomes for substance use disorders.  It was also reported that 
the experimental conditions, a Psychoeducational Therapy group and an Adolescent Group 
Therapy group, significantly reduced illicit substance use from the baseline measures. 
Orchowski & Johnson (2015) provided a narrative review of the efficacy of group 
treatment for alcohol use disorder and compared 15 articles by approach to treatment (Allsop et 
al., 1997; Burtscheidt et al., 1999; Burtscheidt et al., 2001; Conners & Walitzer, 2001; Cooney et 
al., 1991; Kadden et al., 1998; Kadden et al., 2001; Litt et al., 2003; Monti et al., 2001; O’Malley 
et al., 2001; Sandahl et al., 1998; Sandahl et al., 2004; Walitzer & Conners, 2007; Wetzel et al., 
2004; Wolwer et al., 2001).  Three comparisons of approaches to treatment were reviewed, i.e. 
group cognitive-behavioral, group brief dynamic/ interactional psychotherapies, and combined 
pharmacological/ group treatments.  The results were mixed as only one or two studies per 
comparison were found to support group treatment efficacy by each specific approach to 
treatment.  A limitation of the review was that only two of the reviewed articles reported effect 
sizes.  Orchowski & Johnson concluded that group treatment literature is in its infancy compared 
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to the amount of studies that are published on the impact of approach to treatment for individual 
treatment. 
Sokol et al. (2018) conducted a systematic review of group-based opioid treatment 
(GBOT) which operationally defined GBOT as treatment programs for individuals with opioid 
use disorder receiving buprenorphine and group treatment concurrently.  There were no previous 
reviews on GBOTs.  The results indicated that the existent literature was scarce, as only ten 
articles were identified.  Of the 10 studies, four focused on shared medical appointments (Berger 
et al., 2014; Doorley et al., 2017; Roll et al., 2015; Suzuki et al., 2015) and six described utilizing 
group treatment (Imani, Atef Vahid, Garraee, Noroozi, et al., 2015; Lander et al., 2016; Mitchell 
et al., 2013; Miotto et al., 2012; Pugatch et al., 2014; Raisch et al., 2012).  The researchers stated 
that none of the studies were adequately designed to compare treatment efficacy of group 
treatment versus medication-alone or individual treatment.  Limited conclusions could be made 
due to the small number of studies, however, there was no strong evidence to suggest that 
concurrent group treatment improved substance use outcomes.  Further research is needed to 
provide a better understanding of the impact of group treatment for opioid and other substance 
use disorders. 
Lo Coco et al. (2019) performed a systematic review and meta-analysis of randomized-
controlled trials that included 33 studies of 34 treatment conditions.  Of the 3951 patients, 2103 
were randomly assigned to intervention groups and 1848 to control groups.  The average age of 
patients was 38.2 years and 36.2% identified as female.  The included studies compared group 
treatment to a control group in a total of 34 comparisons, group treatment to no treatment control 
groups in nine studies, and group treatment to individual treatment in seven studies, and group 
treatment to other treatments in 18 studies.  Treatment outcomes were categorized as abstinence, 
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frequency of substance use, substance use disorder and co-occurring mental health symptoms, 
and attrition.  
Results for abstinence were significant and group therapy demonstrated small effects for 
each comparison, group vs. no treatment, g = 0.28 and 95% CI [0.04, 0.52]; group vs. individual 
treatment, g = 0.34 and 95% CI [0.06, 0.62]; and group vs. other treatments g = 0.29 and 95% CI 
[0.07, 0.50].  Results for frequency of substance use and symptoms of substance use disorders 
were not significant.  Results for co-occurring mental health symptoms were significant medium 
effects when comparing the effect of group treatment to no treatment, g = 0.64 and 95% CI 
[0.38, 0.90]; however, there were no significant results when comparing the effect of group 
treatment to individual treatment or other treatments.  Attrition rate was 34% overall and there 
were no significant differences in rate of attrition for group vs. no treatment, RR = 0.96, 95% CI 
[0.83, 1.12], k = 5; group vs. individual treatment, RR = 1.01, 95% CI [0.82, 1.23], k = 5; and 
group vs. other treatments, RR = 1.03, 95% CI [0.94, 1.13], k = 15.  Few studies included follow 
up treatment outcome measures within 12 months of the group intervention; however, significant 
medium effects for abstinence were found when comparing group vs. no treatment, g = 0.67 and 
95% CI [0.40, 0.93], k = 5, I2 = 0%.  These results provide some evidence of group treatment 
effectiveness on abstinence. 
Summary 
In a 25-year retrospection of small group process and outcome research, Burlingame and 
Jensen (2017) concluded that group treatment for adults and adolescents with substance use 
disorders produce moderate positive effects.   However, based on the available literature, it 
appears that research on group treatment is scarce (Orchowski & Johnson, 2012; Sokol et al., 
2018; Weiss, 2004).  The shortage of evidence supporting the effectiveness of group treatment is 
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concerning as group treatment is the most common intervention when treating substance use 
disorders.  The most recent review by Lo Coco and colleagues (2019) provided some evidence 
that group treatment was effective for abstinence outcomes on a global scale; however, results 
for frequency of substance use and symptoms of substance use disorders were not significant.  It 
is also a concern that to date there has not been a review focused on treatment philosophies 
Abstinence and Harm Reduction as that is the current and ongoing controversy within the field 
of treatment for substance use disorders.  Only one previous synthesis provided a comparison 
that was related to the inquiry of this study.  In Weiss and colleagues’ (2004) systematic review, 
Pomerleau and colleagues (1978) compared behavioral group therapy with the treatment goal of 
reduced alcohol use to “traditional” treatment with abstinence as the treatment goal and found 
that individuals in the behavioral group therapy demonstrated greater reduction in alcohol use 
and greater retention in treatment than did individuals in the “traditional” treatment group.  In 














Methodology is defined in this chapter.  All methods were determined a priori.  The 
purpose of this study was to conduct a systematic review of published literature on group 
treatment for substance use disorders and using meta-analysis to provide information related to 
the primary research question, Is there a significant clinical and statistical difference in group 
treatment effectiveness when comparing group treatment by Harm Reduction or Abstinence 
treatment philosophies?  This study follows protocols established in the Meta-Analysis 
Reporting Standards (MARS) for quantitative research synthesis (Cooper, 2018).  In accordance 
to the MARS protocol, the following will be discussed: inclusion and exclusion criteria, 
information sources, study selection, data collection, methods for assessing risk to internal 
validity, methods of synthesis, and publication bias and selective reporting. 
Inclusion and Exclusion Criteria 
Studies were reviewed for eligibility determined by inclusion and exclusion criteria.  
Targeted studies included published scholarly, peer-reviewed journal articles within the past 15 
years, i.e. 2004-2020.  The setting of the study must be in the U.S. and written in the English 
language.  Eligible participant populations included individuals receiving group treatment for 
substance use disorders.  Targeted participants were individuals diagnosed with one or more 
substance use disorders as defined by The Diagnostic and Statistical Manual of Mental 
Disorders, (5th ed.; DSM-5; American Psychiatric Association, 2013).  Individuals diagnosed 
with one or more co-occurring disorders were also be included.  There were no restrictions for 
participant demographics such as age, gender, socioeconomic status, or specialty populations 
such as mandated or incarcerated individuals.     
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Targeted research designs were randomized and non-randomized controlled trials 
studying the effects of group treatment as a psychosocial intervention for treating substance use 
disorder.  Less rigorous designs were assessed for inclusion due to the real-world limitations of 
this type of treatment.  Random design and/or control groups for comparison are often not 
imposed in applied research where consumers of the treatment programs require immediate help 
and are ethically bound to receive services.  Due to this departure from standard practice of 
excluding less than rigorous studies, bias will be a risk factor to the conclusions of this study.  
The Cochrane Collaboration tool will be used to reduce the bias.  Post-test only single group 
designs and systematic reviews will be excluded. 
 The selected studies must involve group treatment as the primary intervention for 
substance use disorder(s).  The operational definition of group treatment for substance use 
disorders is two or more unrelated individuals diagnosed with one or more substance use 
disorders who meet to purposefully to improve wellbeing.  Treatment outcomes must be 
measured in quantitative methods with group treatment as the independent variable and 
substance use disorder outcomes as the dependent variables.  Because there is not yet a 
standardized measure of treatment outcomes for substance use disorders, selected studies will be 
investigated for common definitions of outcome measures such as reduction of substance use.  
Studies with insufficient data reported will be excluded.  The selected studies must also indicate 
treatment philosophy used and provide a direct comparison of Abstinence and Harm Reduction.  
Information Sources 
 Scholarly, peer-reviewed journal articles focused on group treatment as the psychosocial 
intervention used in treating substance use disorders were the target for this search strategy.  The 
following databases were searched: 
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1. Cochrane Central Register of Controlled Trials on Ovid 
2. Science Direct 
3. PsycINFO 
4. CINAHL Plus 
5. PubMed 
 To ensure a comprehensive search strategy and replicability of this study, key terms were 
developed with the help of the dissertation committee and the librarians at Old Dominion 
University.  The following searched terms were used: (“group therapy” or “group 
psychotherapy” or “group treatment” or group) AND (“substance use disorder” or substance* or 
addiction or drug or dependent or co-occurring), where “*” is a wildcard term.  
Study Selection 
 The process of deciding which studies to include in the meta-analysis began with a 
review of journal article titles and abstracts.  Initial results from searched databases included 25 
articles from the Cochrane Central Register of Controlled Trials on Ovid, over 5 million from 
Science Direct, 762 from PsycINFO, 5,200 from CINAHL, and 8,449 from PubMed.  The 
journal titles and abstracts were reviewed for the first 200 articles of each database or further if 
subject relevance was not exhausted by the 200th article.  Relevant articles were downloaded in 
.pdf format for further review.  Articles unavailable for download were search on Google Scholar 
or requested via Interlibrary Loan. 
Data Collection 
A comprehensive search was conducted from March 2019 to May 2020.  Data collected 
from selected studies included study characteristics such as patient population demographics, 
design, objective, setting, and primary outcome(s).  Intervention effects and comparison 
information were also collected.  Data abstracted and extracted was conducted by the doctoral 
candidate on a single occasion which is considered a less robust strategy and may weaken the 
results of the analyses.  
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Methods for Assessing Risk to Internal Validity 
 Four main threats to internal validity have been identified for meta-analyses and 
comparative effectiveness research.  Publication bias, dissimilar studies, poor quality studies, and 
limitation of indirect comparisons (Berlin & Sepeda, 2012, Prendergast et al., 2002).  Publication 
bias denotes that scholarly, peer-reviewed studies represent a bias pool of data because only 
studies with significant outcomes are selected for publication (Bown & Sutton, 2010).  Rosenthal 
(1979) suggests including a certain number of unpublished studies to mitigate the effect of 
publication bias.  Inclusion of dissimilar studies is known as the ‘apples and oranges’ dilemma 
where important differences among treatments are lost due to failure to define the subject 
adequately resulting in too broad of a subject (Eysenck, 1978).  Inclusion of studies with poor 
methodological design is known as the ‘garbage in, garbage out’ dilemma (Bangert-Drowns, 
1986; Slavin, 1986).  Indirect comparisons of outcomes from different studies often produces 
biased results and requires statistical adjustments to improve internal validity (Berlin & Cepeda, 
2012). 
 For the proposed study, several of the threats to internal validity are addressed to mitigate 
the impact of these threats.  The subject was narrowly defined as the impact of group treatment 
for substance use disorder on quantitative treatment outcomes.  Study selection was aided by the 
GRADE approach (Higgins & Green, 2008) and the Cochrane Collaboration Risk of Bias 2 tool 
(Higgins et al., 2011) for quality and risk of bias to improve validity for dissimilar and poor-
quality studies.  Direct comparisons of group treatment interventions by treatment philosophies 
of Abstinence and Harm Reduction will be difficult to obtain, as currently there are no 
standardized measurements of treatment effect for substance use disorder limiting the ability to 
investigate treatment efficacies across studies (Tiffany et al., 2011).  This study will include 
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outcome measures presented in the included studies, but those measures may have to be 
expanded or collapsed to meet requirements for statistical power (Balkin & Sheperis, 2011).  
Heterogeneity of effect sizes will be investigated prior to conducting meta-analyses.   
Summary Measures 
Methods of Synthesis 
Data was converted to standardized mean differences (Cohen’s d), as needed, then 
transformed to bias-corrected standardized mean differences (Hedges’ g) to create a common 
index (Borenstein et al., 2009).  The formula for calculating Hedge’s (g) is (M1 – M2)/(SD*pooled).  
Random-effects model meta-analyses was used due to assumed heterogeneity within and 
between studies (Bown & Sutton, 2010; Conn et al., 2012).  Meta-analysis was used to compute 
effect sizes for targeted treatment outcomes to compare treatment philosophies.  Conversion of 
effect size metrics to their original form was conducted to enhance meaningfulness when 
necessary for clearer clinical interpretation.  All calculations were conducted using RevMan 5.4.   
Publication Bias and Selective Reporting 
 Publication bias and selective reporting is due to a higher proportion of studies with 
positive and significant results represented in published in scholarly, peer-reviewed journals than 
studies with negative and/or insignificant results which are often unlikely to be published 
(Higgins & Green, 2008).  This inflation of representation within published literature influences 
validity and generalizability of meta-analyses (Lin & Chu, 2018).  Methods used to mitigate the 
impact of publication bias were to identify unpublished studies and unreported data.  Publication 






Results of the systematic review and meta-analysis are reviewed in this chapter.  The 
purpose of this study was to compare group treatment effectiveness for substance use disorders 
(SUDs) by treatment philosophies of Abstinence and Harm Reduction within the U.S.  This 
chapter describes study selection, study characteristics, results of individual studies, synthesis of 
results, summary of findings, assessment of internal validity of individual studies, publication 
and reporting bias, and adverse and harmful effects. 
Study Selection 
Over 100 articles were identified in the initial review of journal article titles and 
abstracts.  Upon further review of the entire articles, 10 were excluded because group treatment 
was not the independent variable of inquiry, 17 were excluded due to no reported outcome 
measures of substance use disorders as the dependent variable(s), one was excluded because of 
insufficient outcome measures of SUDs, and one was excluded due to the participant population 
where there was no diagnosis of substance use disorder, as it was a prevention intervention.  
Therefore, 76 articles met the inclusion criteria of group treatment as the targeted independent 
variable and outcome measures of substance use disorders as the dependent variable(s).   
The remaining 76 articles were reviewed with special attention given to treatment of 
participants and explicit language used by study authors to determine if Harm Reduction or 
Abstinence treatment philosophies were indicated within the manuscripts.  Once treatment 
philosophies were identified, a further review to determine if head-to-head comparisons by 
treatment philosophies Abstinence and Harm Reduction were the focus of the comparative 
studies.  Thirteen articles indicated direct comparisons of treatment philosophies Abstinence and 
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Harm Reduction and were reviewed for adequate quantitative data for abstraction.  Eight articles 
were excluded due to outcome measurements for SUDs reported as change scores.  Because 
standard deviations of change scores were not reported and are considered missing data (Higgins 
& Green, 2008), the articles were excluded for insufficient data.  Five articles reported sufficient 
data and were included for meta-analysis.  The study selection process of inclusion criteria 
application is detailed in Table 1.  A full list of excluded articles and rationale for exclusion is 
provided in Table 4 in Appendix A. 
Table 1 
Meta-Analysis Inclusion Criteria 
Criteria  n 
Published between 2004-2020, conducted in U.S. and written in English, 
utilized quantitative methodology, not a meta-analysis 
105 
Group treatment as IV and outcome measures of SUDs as DV 76 
Comparison of Harm Reduction and Abstinence treatment philosophy 13 
Sufficient data reported (M, SD) 5 
Study Characteristics  
Data collected from selected studies included study characteristics such as patient 
population demographics, design, objective, setting, primary outcome(s).  Study characteristics, 
quality, and risk of bias are presented in Table 2.  A brief overview of each included study is also 
provided below. 
Miotto and colleagues (2012) recruited potential participants for their study from 
September 1999 to December 2000 by marketing methods with special emphasis on female 
recruitment from local treatment programs.  Participants were screened for eligibility.  Eligibility 
requirements were a diagnosis of opioid use disorder without any other concurrent substance use 
disorders except for tobacco use disorder, no known concurrent medical or psychiatric conditions 
that would interfere with treatment, and no methadone use for the past 30-days or concurrent 
enrollment in a methadone program.  Females were required to use birth control measures if they 
37 
were of reproductive age and were excluded from the study if pregnant or breast-feeding.  The 
overall sample demographics were 58% male and 42% female, predominantly 58% White and 
Hispanic 28%, with an average age of 35 years old.  A total of 94 participants met eligibility, 
began induction onto buprenorphine, and were randomly assigned to one of three treatment 
settings.  Each treatment setting provided distinct psychosocial interventions and buprenorphine 
for medication-assisted treatment of opioid use disorder.   
Treatment settings included (1) a behaviorally oriented psychosocial treatment referred to 
as the manualized Matrix Model (MMM) that included weekly group treatment provided by a 
master’s level clinician; however, attendance was not mandatory and therefore this condition is 
considered as the Harm Reduction condition for this study, (2) an Opioid Treatment Program 
(OTP) that included a schedule of treatment sessions weekly for the first six weeks and then 
monthly for up to one year provided by a certified drug and alcohol counselor, and (3) a primary 
care setting where a physician provided support and education about substance use and recovery.  
Treatment in the OTP condition is considered as the primary Abstinence condition for this study 
due to the emphasis on mandatory treatment attendance and participation on traditional topics 
such as relapse prevention, managing cravings, and recovery.  The participants randomly 
assigned included 33 to MMM with 42% who identified as female, 28 to OTP with 23% female, 
and 33 to Primary Care with 48% female, respectively.  There were no significant differences at 
baseline measure of drug use characteristics.   
A study by Nyamathi and colleagues (2011) also evaluated the effectiveness of three 
programs that offered distinct psychosocial interventions while providing medication-assisted 
treatment for opioid use disorder, i.e. motivational interviewing group treatment (MI-G), 
motivational interviewing individual treatment (MI-S), and nurse-led hepatitis health promotion 
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group treatment (HHP).  Motivational interviewing (MI) is non-confrontational and conveys a 
neutral stance towards substance abuse as the primary goal of MI is to improve an individual’s 
motivation to consider change(s).  Because of this, the motivational interviewing group treatment 
(MI-G) is considered the primary Harm Reduction condition and the nurse-led hepatitis health 
promotion group treatment (HHP) is considered the Abstinence condition due to its focus on 
information dissemination as the goal of the treatment intervention. 
Individuals were made aware of the study by flyers posted in five Methadone 
Maintenance clinics in the Los Angeles and Santa Monica areas.  Eligibility for individuals to be 
recruited included receiving methadone as a medication-assisted treatment for opioid use 
disorder for the past three months, ages 18 to 55 years old, and self-reports of moderate to heavy 
alcohol use.  A total of 256 participants met eligibility.  Baseline measures were collected from 
February 2007 and May 2008 including socio-demographic information, a screen for alcohol use 
and severity, and a health history related to hepatitis.  The overall sample demographics were 
59% male and 41% female, predominantly 45% Black and 27% Latino, with an average age of 
52 years old.  There were no significant differences in participant characteristics at baseline.  
Participants were randomly assigned to one of the three programs, 79 to MI-G with 42% who 
identified as female, 90 to MI-S with 40% female, and 87 to HHP with 41% female, respectively.  
Each provided three 60-minute interventions. 
Rosenblum and associates (2005) recruited participants for their study using flyers at a 
soup kitchen in New York City.  Individuals that were eligible for inclusion were at least 18 
years old, self-reported concerns about past and current substance use, and expressed interest in 
participating in the study.  Eligible and interested individuals attended an initial appointment and 
were interviewed and tested for HIV and drug use.  The overall sample demographics were 82% 
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male and 18% female, predominantly 68% Black, 15% Hispanic, and 17% White/ Other, with an 
average age of 42 years old.  A total of 290 participants met eligibility and were randomly 
assigned to one of two treatment conditions.  Treatment conditions included the experimental 
group where individuals received an intervention titled Service Outreach and Recovery (SOAR) 
which included two separate sequential therapies provided by master’s level clinicians with 
additional certification to provide treatment for SUDs, Motivational Enhancement for Recovery 
(MER) and Education and Skills for Recovery (ESR).  The control condition where individuals 
received Information and Referral (I&R) and peer support.  A total of 151 were randomly 
assigned to the SOAR condition of which 17% identified as female and 139 were randomly 
assigned to the I&R condition of which 18% identified as female. 
Motivational Enhancement for Recovery (MER) group treatment was offered three times 
per week for four weeks.  Similar in approach to motivational interviewing, the MER group 
therapist offered participants a safe space free from judgment or imposing solutions to explore 
the impact of substance use both good and bad.  The therapist listened, reflected neutrality 
toward substance use, and provided empathy and affirmations.  Once completing MER, 
individuals entered the second module, Education and Skills for Recovery (ESR).  ESR group 
treatment was offered three times per week for 12 weeks and utilized cognitive-behavioral 
approach to treatment for SUDs.  Participant attendance to group treatment was encouraged; 
however, was not mandatory and those who attended sporadically continued to be welcome to 
the group.  The SOAR condition is considered the Harm Reduction Condition. 
Weiss and associates (2007) conducted a randomized controlled trial for individuals with 
co-occurring bipolar and substance use disorders by recruiting from within McLean Hospital’s 
programs with referrals and posted flyers.  A total of 62 individuals met inclusion criteria of 
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diagnosis of the co-occurring disorders, were at least 18 years of age, self-reported substance use 
within the past 60 days, and were actively taking medication for bipolar disorder for more than 
two weeks.  Exclusion criteria included current psychosis, imminent harm to self or others, or 
engagement in other group treatment or treatment at a residential facility where substance use is 
restricted.  The overall sample demographics indicated the average age of participants was 42 
years old and 93.5% identified as White.  Participants were randomized to the experimental 
condition, 31 individuals with 52% identifying as female to Integrated Group Therapy (IGT), or 
to the control condition, 31 individuals with 52% identifying as female to Group Drug 
Counseling (GDC).  Each treatment condition was delivered once weekly for one-hour over the 
course of 20 weeks.   
Integrated Group Therapy (IGT) was provided by doctoral and master’s level clinicians 
with at least three years of experience working with co-occurring mental health and substance 
use disorders.  The theoretical approach of IGT was an adaptation of cognitive-behavioral 
therapy to include a focus on the interaction of thoughts and behaviors for both bipolar and 
substance use disorders.  Each week participants would “check-in” and self-report to the group 
on mood, medication compliance, risky scenarios experienced, and on substance use.  The 
inclusion of reported substance use without negative consequences, leveraged treatment, or 
removal from treatment and the study deems the IGT group the Harm Reduction condition. 
Group Drug Counseling (GDC) was also provided once weekly for one-hour for 20 weeks.  
Master’s level clinicians with more than three years of experience working with co-occurring 
disorders provided a treatment approach that was designed to mirror treatment as usual provided 
at community treatment programs for SUDs.  The primary goal of treatment was to facilitate 
abstinence which deems this treatment as the Abstinence condition of this study. 
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Weiss and associates (2009) adjusted their previous studies (2000; 2007) to create a 
“community friendly” version of Integrated Group Therapy (IGT) for individuals with co-
occurring bipolar and substance use disorders.  The duration of treatment was reduced for both 
the experimental and control conditions from the previous 20-week duration (2007) to 12-weeks 
to better reflect real-world implementation of the group treatment intervention.  Another 
adjustment for this study included using only certified drug and alcohol counselors instead of 
more extensively trained clinicians also to better represent real-world conditions.  The 
approaches to treatment remained constant and the hour-long weekly Integrated Group Therapy 
(IGT) sessions were deemed as the HR condition and the Group Drug Counseling (GDC) 
condition was considered the Abstinence condition.  Participants were randomly assigned, 31 
individuals with 41% identifying as female to IGT and 30 individuals with 41% identifying as 
female to GDC.  Overall sample demographics indicate the average age of a participant was 38 
years old and 92% of participants identified as White.  
Results of Individual Studies 
 Overall, five studies met the inclusion criteria.  Results from individual studies are 
provided below.  Means and standard deviations were used to calculate Hedge’s g effect sizes for 
the outcome measure of substance use and are summarized at each time point of data collection.  
Data for results of individual studies are provided in Table 3.  In four out of the five studies, 
individuals randomized to the Harm Reduction condition had greater reduction in substance use 
(Nyamathi et al., 2011; Rosenblum et al., 2005; Weiss et al., 2007; Weiss et al., 2009) than did 
individuals in the Abstinence condition (Miotto et al., 2012); however, not all differences were 
clinically or statistically significant.  Effect sizes of 0.20 are considered small, 0.50 medium, or 
0.80 and greater as large (Cohen, 1988).  
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Table 2 
Characteristics of Included Studies 
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Rosenblum et al. (2005) reported significant results for the reduction of days using 
substances for both conditions from baseline to five-month follow-up (P < .01) measured by the 
Time-Line Follow Back interview (Sobell & Sobell, 1996); however, the HR condition had a 
greater impact with a medium effect size (g = .49) compared to the control condition (g = .31). 
Nyamathi and colleagues (2011) measured substance use as change per day of drug 
intake as a composite drug score that represents the frequency and severity of self-reported 
recall.  Reductions in average daily drug intake reduced significantly as per self-report for past 
30 days (P < .0001).  The baseline measure of self-report of substance use over the past six 
months revealed a trend of declining substance use over time (P = .09).  There were no 
significant differences between the three program types.  The effect size of the HR condition 
Motivational Interviewing- Group (MI-G) demonstrated the greatest impact (g = .39), followed 
by the Motivational Interviewing- Single (MI-S), individual sessions, (g = .24).  The control 
condition of nurse-led Hepatitis Health Promotion (HHP) group sessions were least impactful (g 
= .10). 
Weiss et al. (2007) measured treatment efficacy by days of substance use using the 
Addiction Severity Index (McLellan et al., 1992), the Timeline Follow-Back technique (Sobell & 
Sobell, 1992), and urine drug screen analysis.  Overall, substance use decreased during 
treatment; however, the HR condition, Integrated Group Therapy (IGT), demonstrated greater 
impact on reducing days of substance use (g = .71) than the Abstinence condition, Group Drug 
Counseling (GDC) (g = .17).  Days of substance use during treatment for IGT decreased by 6.4 
days (P < .001) compared to 1.7 days for GDC.  At follow-up, days of substance use increased in 
the GDC group by 0.3 days; however, the IGT group continued to demonstrate a reduction of 5.7 
days of substance compared to the baseline assessment. 
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Weiss et al. (2009) also measured treatment efficacy by days of substance use using the 
Addiction Severity Index (McLellan et al., 1992), the Timeline Follow-Back technique (Sobell & 
Sobell, 1992), and urine drug screen analysis.  Overall, treatment efficacy of both conditions 
demonstrated changes in mean substance use larger than one standard deviation at both follow-
up measures.  The effect sizes for the HR condition, Integrated Group Therapy (IGT), at three 
and six month follow-ups were large (g = 1.65) and (g = 1.57) as were the effect sizes for the 
Abstinence condition, Group Drug Counseling (GDC), (g = 1.36) and (g = 1.02). 
While both treatment conditions were highly impactful, the HR condition outperformed the 
Abstinence condition overall and at the three- and six-month follow-up measures.  Days of 
substance use for IGT decreased by 14.3 days (P < 0.001) at the three-month measure which 
represents the end of treatment and 11.6 days (P < 0.001) for GDC.  At the six-month follow-up, 
IGT decreased days of substance use by 13.2 days (P < 0.001) which was more than GDC 
decreased days of substance use of 10.2 (P < 0.001). 
Miotto et al. (2012) did not report significant results when three treatment settings were 
compared for reducing opioid use measured by the Treatment Effectiveness Score (Ling et al., 
1998), the proportion of negative urine drug screens, at the nine- and 20-week follow up 
appointments (F = 1.96; P = 0.15).  The effect sizes were less than small with the HR condition 
(g = .11), Opioid Treatment Program (OTP) (g = .04), and primary care (PC) (g = .06). 
Synthesis of Results 
 Although the selected studies used different measurements of substance use, meta-
analysis produces unitless effect sizes that can be combined for an aggregate estimate of 
effectiveness for the targeted treatment outcome substance use (Conn et al, 2012).  A single 
time-point of the longest follow-up from each study was selected as the final measurement 
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values for the targeted outcome measure of substance use to maximize the available data 
(Higgins & Green, 2008).  Results of the meta-analysis are provided in Table 4 and Figure 1.  
Table 4 
Aggregate Standardized Mean Difference 
Study Harm Reduction Abstinence Weight Std Mean 
Difference, IV, 
Random, 95% CI 
 M SD n M SD n   
Miotto et al. 
(2012) 
0.33 0.37 33 0.22 0.27 28 14.0% 0.33 [-0.18, 0.84] 
Nyamathi et 
al. (2011) 
0.04 1.51 79 0.12 1.49 87 25.7% -0.05 [-0.36, 0.25] 
Rosenblum 
et al. (2005) 
8.30 10.80 151 10.30 11.40 139 31.9% -0.18 [-0.41, 0.05] 
Weiss et al. 
(2007) 
6.00 9.10 31 12.00 10.80 31 14.1% -0.59 [-1.10, -0.08] 
Weiss et al. 
(2009) 
5.20 7.00 31 7.90 10.70 30 14.2% -0.30 [-0.80, 0.21] 
Total  
(95% CI) 
  325   315 100.0% -0.15 [-0.38, 0.08] 
Heterogeneity: Tau2 = 0.03; Chi2 = 7.14, df = 4 (P = 0.13); I2 = 44% 
Test for overall effect: Z = 1.29 (P = 0.20) 
 
Figure 1. 
Forest Plot of Standardized Mean Difference, Inverse Variance, Random-Effects Model, 95% CI 
 
Overall, there was not a statistically significant difference between outcomes of substance 
use by treatment philosophy (Z = 1.29) and (P = 0.20).  However, there may be a clinically 
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significant difference due to the aggregate standardized mean difference (-0.15, CI [-0.38, 0.08]) 
which favors Harm Reduction over Abstinence in the reduction of substance use. 
Heterogeneity, measured as I2 = 44%, may not be important or may represent a moderate 
level of clinical and methodological diversity within the selected studies.  Common thresholds 
for I2 are 0%-40% might not be important and 30%-60% may be interpreted as moderate 
(Higgins & Green, 2008).  The p-value was not significant (P = 0.13); however, random-effects 
model was used to calculate the overall effect as a strategy for addressing heterogeneity. 
Summary of Findings 
The aim of this systematic review and meta-analysis was to provide an answer to the 
following primary research question: Is there a significant statistical and clinical difference in 
group treatment effectiveness when comparing group treatment by Harm Reduction or 
Abstinence treatment philosophies?     
RQ1: Is there a significant difference of group treatment effectiveness between 
Abstinence and Harm Reduction treatment philosophies?   
H1: It is hypothesized that group treatment will remain an effective intervention to treat 
substance use disorder between philosophies. 
Ho: There are no significant difference between group comparisons. 
The synthesis of results indicated that there was not a statistical difference of group 
treatment effectiveness between Abstinence and Harm Reduction treatment philosophies and the 
null hypothesis was accepted.  Overall, there was not a statistically significant difference 
between outcomes of substance use by treatment philosophy (Z = 1.29) and (P = 0.20).  
However, there may be a clinically significant difference due to the aggregate standardized mean 
difference (-0.15, CI [-0.38, 0.08]) which favors Harm Reduction over Abstinence in the 
49 
reduction of substance use.  The alternative hypothesis that group treatment will remain an 
effective intervention between Abstinence and Harm Reduction treatment philosophies for 
substance use disorders was sustained by results of individual studies.  Results of individual 
studies indicated that in four out of the five studies, individuals randomized to the Harm 
Reduction condition had greater reduction in substance use (Nyamathi et al., 2011; Rosenblum et 
al., 2005; Weiss et al., 2007; Weiss et al., 2009) than did individuals in the Abstinence condition 
(Miotto et al., 2012); however, not all differences were clinically or statistically significant.   
Assessment of Internal Validity of Individual Studies 
Four main threats to internal validity were identified for meta-analyses and comparative 
effectiveness research in Chapter III.  Publication bias, dissimilar studies, poor quality studies, 
and limitation of indirect comparisons (Berlin & Sepeda, 2012, Prendergast et al., 2002).  
Publication and reporting bias will be reported in the next section.  The included studies were 
assessed for quality using the GRADE approach (Higgins & Green, 2008).  Four out of the five 
studies were randomized controlled trials which have a quality rating of high (Nyamathi et al. 
(2012; Rosenblum et al., 2005; Weiss et al., 2007; Weiss et al., 2009).  Miotto et al. (2012) used 
an underlying methodology of a randomized study without a control group due to assignments to 
treatment settings and was assigned a quality rating of moderate.  Studies which did not provide 
direct comparisons were excluded. 
Publication and Reporting Bias 
  Reporting bias is a distortion of presented information that can be due to different types 
of selective disclosure by the researcher (Richards, 2019).  Publication bias is due to the greater 
likelihood of publication for scientific inquiries that resulted in significant findings.  Methods 
used to mitigate the impact of publication bias were to identify unpublished studies and 
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unreported data.  The researcher experienced time lag bias for one study that was not yet 
published at the time of data collection.  The researcher also experienced insufficient data from 
the reported results that would enable inclusion for this study.  A comprehensive search of 
multiple information sources for studies that met inclusion criteria was conducted to avoid 
reporting bias.  It is important to note that to meet inclusion criteria for this study treatment 
philosophies of Harm Reduction and Abstinence had to be explicitly denoted which may be a 
source of unresolved reporting bias.  Language bias was also present in this study as the targeted 
articles were selected for treatment outcomes within the U.S. and written in English.   
Adverse and Harmful Effects 
 Adverse effects include withdrawal or attrition rate from individual studies, management 
of incomplete outcome data, and differences in blinding (Higgins & Green, 2008).  Withdrawal, 
drop out, and attrition are common when treating substance use disorders (Palmer et al., 2009).  
Attrition rates were provided for each included study and attempts were made to complete 
missing outcome data.  Differences in blinding within studies may attribute to adverse effects as 
Miotto et al. (2012), Nyamathi et al. (2011), and Rosenblum et al. (2005) did not use blinding 
whereas Weiss et al. (2007) and Weiss et al. (2009) blinded the lead psychologist from the 
participant’s treatment conditions to reduce adverse effects.  No harmful effects for group 









In this chapter, a summary of the evidence, generalizability, conclusions, and 
implications are discussed.  The primary purpose of conducting a comparison of group treatment 
effectiveness by treatment philosophy provided information that is helpful to decision-making 
stakeholders.  Evidence from comparative effectiveness research is important to policymakers, 
consumers, and providers.  Results of this comparative effectiveness research study will help 
guide clinical practices for treating substance use disorders.  An overview of previous chapters is 
provided. 
Chapter I provided a historical background of the evolution of treatment for substance 
use disorders (SUDs) that developed into two current treatment philosophies Abstinence and 
Harm Reduction (HR).  The problem statement was a need for a review of group treatment 
effectiveness for treating substance use disorders within the U.S., as group treatment is the 
dominant service provided when treating substance use disorders (SAMHSA, 2015a).  The most 
recent review focused on global effectiveness of group treatment for SUDs (Lo Coco et al., 
2019).  The purpose of this study was to investigate whether group treatment is an effective 
treatment intervention for substance use disorders in the U.S. by comparing group treatment 
philosophies of Abstinence and Harm Reduction by reviewing and appraising the current 
literature, as there was no literature to date of comparative effectiveness research on group 
treatment interventions by treatment philosophy identified in the literature.   
The rationale of examining the impact of group treatment on substance use will provide 
treatment providers with applicable knowledge to improve treatment programs and protocols and 
may help to determine best practices and policies for treating substance use disorders such as 
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employing effective, evidence-based interventions.  The significance of the contribution of this 
study is to provide up-to-date information on the effectiveness of treatment philosophies that will 
ultimately provide a basis to determine a more unified model of treating substance use disorder, 
as currently there is no unified theoretical model that comprehensively explains all aspects of 
substance use (Skinner & Aubin, 2010).   
Delimitations of this study included a departure from standard practice of excluding less 
than rigorous studies, such as randomized controlled trials, due to the real-world nature of this 
inquiry.  Direct comparisons of Abstinence and Harm Reduction were deemed difficult to obtain 
as there are no current standardized measures of treatment effect for substance use disorders.  
Outcome variables, heterogeneity, and risk bias were determined to be risk factors to this study 
and efforts were determined a priori to mitigate the impact of the delimitations.  Limitations of 
this study were a possible low number of studies that could meet inclusion criteria given the 
practical limitations of clinical settings and ethical concerns for comparison and control group 
assignments.  Applied research is also limited by moderating, mediating, and confounding 
variables such as treatment fidelity, therapist adherence to treatment philosophy, attrition, and 
open enrollment groups. 
This study is based on the conceptual framework of prior theory and research, utilizing 
the paradigm of post-positivism, in that the purpose of this study is to arrive at a conclusion of 
effectiveness by comparison that will guide clinical practice and policies for SUD treatment.  
The primary assumption is that this study will employ rigorous measures to minimize erroneous 
conclusions, as the quality of the systematic review is dependent on its methodology.  The 
secondary assumption is that systematic reviews provide better evidence than individual studies 
in comparative effectiveness research (Berlin & Cepeda, 2012). 
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Chapter II presented a literature review of previous syntheses to establish a need for a for 
a review of group treatment effectiveness for substance use disorders (SUDs) by treatment 
philosophy within the U.S.  Literature reviewed, appraised, and synthesized includes previous 
systematic reviews with meta-analyses, narrative, or qualitative summaries.  Six previous 
syntheses were identified in the literature that provide further evidence regarding group treatment 
effectiveness for substance use disorders (Engle & MacGowan, 2009; Lo Coco et al., 2019; 
Orchowski & Johnson, 2012; Sobell & Sobell, 2011; Sokol et al., 2018, Weiss et al., 2004).  In 
summary, based on the available literature, it appears that research on group treatment is scarce 
(Orchowski & Johnson, 2012; Sokol et al., 2018; Weiss, 2004).  Only one previous synthesis 
provided a comparison that was related to the inquiry of this study (Weiss et al., 2004).  And  
the most recent review by Lo Coco and colleagues (2019) provided some evidence that group 
treatment was effective for abstinence outcomes on a global scale; however, results for frequency 
of substance use and symptoms of substance use disorders were not significant.  In summary, a 
current a review of group treatment effectiveness for substance use disorders (SUDs) by 
treatment philosophy within the U.S. is needed. 
Chapter III defined the methodology of this study.  All methods were determined a 
priori.  Inclusion criteria were published scholarly, peer-reviewed journal articles published 
between 2004 and 2020, conducted in the U.S., and written in English.  Studies must include 
quantitative methodology with group treatment as the independent variable and outcome 
measures of SUDs as the dependent variable(s).  Studies were excluded that did not provide 
direct comparisons of Abstinence and Harm Reduction.  Studies were also excluded that did not 
report sufficient data such as means and standard deviations.  Information sources, study 
selection, and data collection were also reviewed in this chapter.  Five information sources were 
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used to conduct the systematic review and articles that were unavailable were further searched 
through Google Scholar and/or requested through Interlibrary Loan.  Data were collected from 
March 2019 to May 2020 by the doctoral candidate on a single occasion which may weaken the 
results of the current analyses as it is a considered a less robust data collection strategy.  Methods 
for assessing risk to internal validity such as publication bias, dissimilar studies, poor quality 
studies, and limitation of indirect comparisons were discussed. 
Summary measures such as methods of synthesis and publication bias and selective 
reporting were reviewed.  For results of individual studies, data was converted to standardized 
mean differences (Cohen’s d), as needed, then transformed to bias-corrected standardized mean 
differences (Hedges’ g) to create a common index (Borenstein et al., 2009).  The formula for 
calculating Hedge’s (g) is (M1 – M2)/(SD*pooled).  Random-effects model meta-analyses was used 
due to assumed heterogeneity within and between studies (Bown & Sutton, 2010; Conn et al., 
2012).  Meta-analysis was used to compute an aggregate standardized mean difference for 
substance use to compare the two treatment philosophies.  All calculations were conducted using 
RevMan 5.4.  Methods used to mitigate the impact of publication bias were to identify 
unpublished studies and unreported data.  Publication bias and selecting reporting for individual 
studies were further discussed in Chapter IV. 
Chapter IV presented the results of this systematic review and meta-analysis.  Study 
selection included a review of over 100 articles identified in the initial review of journal article 
titles and abstracts and were further reviewed for inclusion and exclusion criteria.  A total of 5 
studies were included and study characteristics were described (Miotto et al., 2012; Nyamathi et 
al., 2011; Rosenblum et al., 2005; Weiss et al., 2007; Weiss et al., 2009).   Results of individual 
studies indicated that in four out of the five studies, individuals randomized to the Harm 
55 
Reduction condition had greater reduction in substance use (Nyamathi et al., 2011; Rosenblum et 
al., 2005; Weiss et al., 2007; Weiss et al., 2009) than did individuals in the Abstinence condition 
(Miotto et al., 2012); however, not all differences were clinically or statistically significant.  A 
synthesis of results indicated there was not a statistically significant difference between 
outcomes of substance use by treatment philosophy (Z = 1.29) and (P = 0.20).  However, there 
may be a clinically significant difference due to the aggregate standardized mean difference (-
0.15, CI [-0.38, 0.08]) which favors Harm Reduction over Abstinence in the reduction of 
substance use.  A summary of findings applied the results to answer the primary research 
question: Is there a significant statistical and clinical difference in group treatment effectiveness 
when comparing group treatment by Harm Reduction or Abstinence treatment philosophies?    
Where the null hypothesis of no significant difference between group comparisons was accepted.  
The alternative hypothesis that group treatment will remain an effective intervention to treat 
substance use disorder between philosophies was sustained.   
Assessment of internal validity of individual studies included the four main threats to 
internal validity that were previously identified for meta-analyses and comparative effectiveness 
research in Chapter III.  Attempts were made to mitigate these threats such as assessing for 
quality, risk of bias, heterogeneity, excluding indirect comparisons, and utilizing resources to 
reduce publication and reporting bias.  The included studies were assessed for quality using the 
GRADE approach (Higgins & Green, 2008).  Four out of the five studies were randomized 
controlled trials which have a quality rating of high (Nyamathi et al. (2012; Rosenblum et al., 
2005; Weiss et al., 2007; Weiss et al., 2009).  Miotto et al. (2012) used an underlying 
methodology of a randomized study without a control group due to assignments to treatment 
settings and was assigned a quality rating of moderate.  A low risk of bias was assigned to all 
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included studies with guidance from the Cochrane Collaboration Risk of Bias 2 Tool (Higgins et 
al., 2011).  Studies which did not provide direct comparisons were excluded.  Resources such as 
Google Scholar and Interlibrary Loan were used to help identify unpublished studies and 
unreported data.  The researcher experienced time lag bias and insufficient data that may have 
altered inclusion of other related studies; however, a comprehensive search of multiple 
information sources for studies that met inclusion criteria was conducted to avoid reporting bias.  
Language bias was also present in this study as the targeted articles were selected for treatment 
outcomes within the U.S. and written in English due to the nature of this inquiry.  It is important 
to note that to meet inclusion criteria for this study treatment philosophies of Harm Reduction 
and Abstinence had to be explicitly denoted which may be a source of unresolved reporting bias.   
Adverse effects include withdrawal or attrition rate from individual studies, management 
of incomplete outcome data, and differences in blinding (Higgins & Green, 2008).  Withdrawal, 
drop out, and attrition are common when treating substance use disorders (Palmer et al., 2009).  
Attrition rates were provided for each included study and attempts were made to complete 
missing outcome data within the study.  Differences in blinding within studies may attribute to 
adverse effects as Miotto et al. (2012), Nyamathi et al. (2011), and Rosenblum et al. (2005) did 
not use blinding whereas Weiss et al. (2007) and Weiss et al. (2009) blinded the lead 
psychologist from the participant’s treatment conditions to reduce adverse effects.  No harmful 
effects for group treatment were found when searched.  
Summary of the Evidence 
The primary research question was answered using a random-effects meta-analysis to 
calculate an overall effect size comparing treatment philosophies Abstinence and Harm 
Reduction.  The primary research question, Is group treatment for substance use disorders 
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effective? resulted in an aggregate standardized mean difference (-0.15, CI [-0.38, 0.08]) which 
favored Harm Reduction over Abstinence in the reduction of substance use.  However, there was 
not a statistically significant difference between outcomes of substance use by treatment 
philosophy (Z = 1.29) and (P = 0.20).  Although, there may be a clinically significant difference 
between the two treatment philosophies as in four out of the five included studies the Harm 
Reduction condition outperformed the Abstinence condition.  These mixed results are consistent 
with findings from the previous syntheses in Chapter II (Engle & MacGowan, 2009; Lo Coco et 
al, 2019; Orchowski & Johnson, 2012; Sobell & Sobell, 2011; Sokol et al., 2018; Weiss et al. 
2004). 
Main findings of this study including results of individual studies and synthesis of results, 
provided an overall quality of the evidence.  Strengths and limitations of these findings include 
inconsistency, imprecision, risk of bias, publication bias, and selective outcome reporting.  An 
alternative explanation for observed results may be due to the ability to use change scores instead 
of a single time-point of the longest follow-up from each study that was selected as the final 
measurement values for the targeted outcome measure of substance use to maximize the 
available data (Higgins & Green, 2008).   
Generalizability 
The generalizability, or external validity, of conclusions for systematic reviews is limited 
(Avellar et al., 2016).  Systematic reviews are designed to investigate effectiveness of treatment 
interventions from previously conducted scientific inquiries on a given subject.  Implications for 
related populations, intervention variations, and dependent (outcome) variables outside of the 
included studies must often be extrapolated from the findings of a systematic review and 
suggested as areas for future study.  Group treatment for substance use disorder may vary greatly 
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depending upon the treatment setting and the therapist adherence to a treatment philosophy.  
Group treatment for substance use disorder may also vary greatly due to individual needs present 
within specific populations, i.e. by substance use disorder and/or co-occurring disorder.  The 
generalizability of the present study is also limited.   
A low number of studies that met the criteria of this study impacts the generalizability of 
the results.  Group treatment effectiveness may not be investigated often due to the difficulty of 
rigorous design in the delivery of services and measuring treatment outcomes.  This is partially 
due to practical limitations of clinical settings and ethical concerns when considering control or 
comparison groups.  Attrition and open enrollment groups wherein attendance varies from 
session to session and structured delivery of treatment which builds over time is not possible 
further compound the ability to establish strong research support (Wendt & Gone, 2017).  Many 
moderating, mediating, and confounding variables exist in this type of applied research.  Some 
examples are treatment fidelity, such as therapist adherence to treatment philosophy and 
counselor competence as a group leader (Collyer et al., 2019), therapeutic alliance, and group 
cohesion (Orchowski & Johnson, 2012).   
Conclusions 
The aim of this systematic review and meta-analysis was to provide an answer to the 
following primary research question: Is there a significant statistical and clinical difference in 
group treatment effectiveness when comparing group treatment by Harm Reduction or 
Abstinence treatment philosophies?     
RQ1: Is there a significant difference of group treatment effectiveness between 
Abstinence and Harm Reduction treatment philosophies?   
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H1: It is hypothesized that group treatment will remain an effective intervention to treat 
substance use disorder between philosophies. 
Ho: There are no significant difference between group comparisons. 
While there were no significant statistical differences of group treatment effectiveness 
between Abstinence and Harm Reduction treatment philosophies there may be a clinical 
significance as Harm Reduction was slightly favored as treatment philosophy over Abstinence 
for the included studies on the outcome of substance use.  Only one previous synthesis provided 
a comparison that was related to the inquiry of this study (Weiss et al., 2004).  Pomerleau and 
colleagues (1978) compared behavioral group therapy with the treatment goal of reduced alcohol 
use to “traditional” treatment with abstinence as the treatment goal.  Similar to this study, 
individuals in the behavioral group therapy demonstrated greater reduction in alcohol use and 
greater retention in treatment than did individuals in the “traditional” treatment group.  Future 
research focused on clearly identified group treatment philosophy is important to provide up-to-
date and a more accurate reflection on the effectiveness for treating substance use disorders.  
Implications 
In the U.S., individuals with high severity of substance use disorders and those involved 
in the criminal justice system are most likely to receive treatment (Johnson et al., 2020).  
Individuals with substance use disorders often find themselves in court-ordered treatment due to 
intoxication, possession of illicit drugs, violent crimes, or drug-seeking property crimes.  The 
Abstinence treatment philosophy is evident within the U.S. Criminal Justice System whereby 
substance use is considered a public health problem (Koppel, 2016).  Treatment providers that 
adhere to the Abstinence treatment philosophy often oppose Harm Reduction treatments such as 
syringe exchange programs, safe injection sites, naloxone medication distribution for opioid 
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overdose, and medication-assisted treatment (Oyemade, 2015).  Generally, individuals receiving 
medication-assisted treatment for substance use disorders are discouraged from attending self-
help Abstinence programs such as Alcoholics Anonymous and Narcotics Anonymous by the 
people in those programs.  The 12-Step philosophy of Abstinence indicates that those receiving 
medication-assisted treatment are not abstinent from drug use although they are in recovery. 
Because therapist adherence to treatment philosophy ultimately impacts treatment outcomes for 
individuals with substance use disorders, further research dedicated to exploring direct 
comparisons of Abstinence vs. Harm Reduction would provide evidence that is critical to public 
policy and treatment programming.   
Theoretical underpinnings of third wave therapies focus on change and acceptance 
(Narayanan & Naaz, 2018).  Harm Reduction is described by Marlatt (1998) as “compassionate 
pragmatism,” where treatment providers accept that individuals use drugs in harmful ways and 
strive to provide quality, evidence-based care to a marginalized population.  This is a paradigm-
shift that contrasts with traditional treatment providers who view individuals with SUDs as 
suffering from the disease of terminal uniqueness and attempt to have the person conform to 
Abstinence treatment philosophy.  Harm Reduction treatment providers appreciate the 
uniqueness of each individual, their journey, and their meaning and purpose (Tatarsky & Marlatt, 
2010).   The focus of treatment is broadened from the substance use itself to the person as a 
whole, where substance use and misuse is but one clinical aspect (Rothschild, 2010).  Treatment 
begins with the client’s needs and personal goals which are stated by the client and is not coerced 
or influenced by the intentions of the treatment program or the treatment providers (Marlatt, 
1996). 
61 
The purpose of comparative effectiveness research is to generate and synthesize data to 
determine the best intervention for the general population (Berlin & Cepeda, 2012; Neely et al., 
2013).  The term ‘effectiveness’ describes the helpfulness of an intervention to diverse people in 
real world clinical settings (Fedson, 1998).  Investigating effectiveness of interventions such as 
group treatment requires published data that can be aggregated across studies to reveal a 
comprehensive measure of its impact on treatment outcomes (Henly, 2016; Higgins, et al. 2011).  
Comparing effectiveness of group treatment for substance use disorders by treatment philosophy 
will help counselors provide evidence-based treatment to meet individual needs clarify both the 
most effective intervention for a specific disorder and for the general population.  Future 
research focused on the effectiveness of group treatment on specific substance use and co-
occurring disorders and patient characteristics may provide information beyond the scope of this 
review that identifies treatment needs to unique populations such as those mandated to treatment. 
Translation of effectiveness evidence into the field of substance use treatment is critical 
at this time because of the high prevalence of SUDs in the U.S., the devastation experienced by 
individuals and families due to the opioid crisis, and the rising costs of healthcare.  
Dissemination and implementation of effectiveness research is critical as currently, less than half 
of U.S. treatment programs offer evidence-based practices (Padwa & Kaplan, 2018) and 
presently there are no federal guidelines or mandates for community-based treatment for 
substance use disorders to employ evidence-based practices (Rieckmann et al., 2011).  However, 
there are recent efforts to improve implementation of evidence-based practices (NIDA, 2015).  
Funding, regulations, and continued education are provided by some States to encourage the 
implementation of evidence-based practices (Robertson et al., 2015).   
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The use of interventions that are not evidence-based conflicts with the American 
Counseling Association’s Code of Ethics (2014) that requires treatment have an empirical or 
scientific foundation where the choice of psychosocial intervention is based upon past research 
that supports the effectiveness of the treatment modality.  It appears that now is a time in 
substance use treatment history where leaders in the field such as educators, providers, and 
supervisors are responsible for the adoption of effective treatment and evidence-based practices 
as an ethical imperative to provide quality care for those receiving services.  The aim of this 
study was to provide evidence of treatment effectiveness that will ultimately improve treatment 
outcomes for substance use disorders, provide guidance for broader implementation of evidence-
based treatment approaches within the U.S., and to provide current information for evidence-
based decision-making.  Continued investigation of treatment effectiveness will provide the 
guidance necessary for improving treatment outcomes for individuals with substance use 
disorders and will provide the information needed to make decisions that impact American 
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